AIP
GPCR icon

Arrowpoint Investment Partners’s Structure Therapeutics GPCR Stock Holding History

Arrowpoint Investment Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
4,645
+455
+11% +$20.1K 0.05% 99
2026
Q1 		$202K Buy
+4,190
New +$287K 0.18% 70

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowpoint Investment Partners's GPCR Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its Structure Therapeutics (GPCR) stake by 11% in Q2 2026, buying an estimated $20.1K and bringing the position to 4,645 shares worth $249K. The position accounts for 0.05% of the portfolio, ranked #99.

Arrowpoint Investment Partners first reported a position in GPCR in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Arrowpoint Investment Partners held 4,645 shares of Structure Therapeutics worth $249K as of Q2 2026.
  • Arrowpoint Investment Partners bought 455 Structure Therapeutics shares in Q2 2026, an estimated $20.1K.
  • Structure Therapeutics made up 0.05% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #99 holding.
  • Arrowpoint Investment Partners first reported a position in Structure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.